Arno Therapeutics, Inc 4
4 · Arno Therapeutics, Inc · Filed Jan 14, 2016
Insider Transaction Report
Form 4
Ruchefsky Steven B
Director
Transactions
- Purchase
Common Stock
2016-01-12$0.35/sh+2,876,633$1,006,822→ 4,472,905 total(indirect: By LLC)
Holdings
- 3,750
Stock Option (right to buy)
Exercise: $8.00Exp: 2020-11-05→ Common Stock (3,750 underlying) - 205,344
Stock Option (right to buy)
Exercise: $2.40Exp: 2023-11-04→ Common Stock (205,344 underlying) - 34,224
Stock Option (right to buy)
Exercise: $2.90Exp: 2024-01-24→ Common Stock (34,224 underlying) - 136,784
Stock Option (right to buy)
Exercise: $0.85Exp: 2024-11-04→ Common Stock (136,784 underlying) - 48,399
Stock Option (right to buy)
Exercise: $0.36Exp: 2025-11-04→ Common Stock (48,399 underlying) - 1,531,861(indirect: By LLC)
2012 Series A Warrants (right to buy)
Exercise: $1.36From: 2013-10-29Exp: 2017-11-26→ Common Stock (1,531,861 underlying) - 1,285,046(indirect: By LLC)
2013 Series D Warrants (right to buy)
Exercise: $2.14From: 2013-10-29Exp: 2018-10-29→ Common Stock (1,285,046 underlying)
Footnotes (8)
- [F1]On January 12, 2016, Commercial Street Capital, LLC purchased 1,448,062 shares for cash consideration and was also issued 1,428,571 shares upon the automatic conversion of $506,821.92 of principal and accrued interest under a 6% unsecured convertible promissory note previously issued to Commercial Street Capital, LLC by the Issuer on October 21, 2015.
- [F2]The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- [F3]Currently exerciseable.
- [F4]Vests in equal 36-monthly installments commencing 12/4/13.
- [F5]Vests in equal 12-monthly installments commencing 2/24/14.
- [F6]Vests in equal 36-monthly installments commencing 12/4/14.
- [F7]Vests in equal 36-monthly installments commencing 12/4/15.
- [F8]As a result of the Issuer's 1/12/16 private placement of common stock at $0.35/share, the exercise price and number of shares subject to the 2012 Series A Warrants and 2013 Series D Warrants were automatically adjusted to the exercise price and shares reflected, pursuant to anti-dilution adjustment provisions.